ProCE Banner Activity

BTK Inhibitor Therapy: Delving Into Evolving Topics, Critical Aspects of Management, and Practice-Changing Data

Slideset Download
Review the most clinically relevant BTK inhibitor data across multiple B-cell malignancies with these downloadable slides, including advances in CLL, MCL, MZL, and Waldenström macroglobulinemia.

Released: May 29, 2020

Expiration: May 28, 2021

No longer available for credit.

Share

Faculty

Farrukh Awan

Farrukh Awan, MD, MS

Associate Professor of Internal Medicine
Division of Hematology
The Ohio State University Comprehensive Cancer Center
Arthur G. James Cancer Hospital and Richard J. Solove Research Institute
Columbus, Ohio

Ian W. Flinn

Ian W. Flinn, MD, PhD

Chief Scientific Officer
One Oncology and Tennessee Oncology
Nashville, Tennesse

Prashant Kapoor

Prashant Kapoor, MD

Assistant Professor of Medicine and Oncology
Consultant
Department of Hematology
Mayo Clinic
Rochester, Minnesota

Provided by

Jointly provided by the Annenberg Center for Health Sciences at Eisenhower and Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by an educational grant from

Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC

Pharmacyclics AbbVie

Faculty Disclosure

Primary Author

Farrukh Awan, MD, MS

Associate Professor of Internal Medicine
Division of Hematology
The Ohio State University Comprehensive Cancer Center
Arthur G. James Cancer Hospital and Richard J. Solove Research Institute
Columbus, Ohio

Ian W. Flinn, MD, PhD

Chief Scientific Officer
One Oncology and Tennessee Oncology
Nashville, Tennesse

Prashant Kapoor, MD

Assistant Professor of Medicine and Oncology
Consultant
Department of Hematology
Mayo Clinic
Rochester, Minnesota